Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

Table 9 Medical cannabis effects on mood disorders at 1, 3, and 12 months in Italian fibromyalgia patients

	Prior MC	With MC	P	Prior MC	With MC	P	Prior MC	With MC	P
	1 month, 30 patients			3 months, 18 patients			12 months, 12 patients
HADS anxiety
Median	13	11	>0.01	12	8.5	>0.01	9	7	>0.01
IQR	7.5	8.25		9.25	11.5		7.25	10.5
Mean	13	11		12	8.5		9	7
± SD	4.3	5.6		4.6	6.3		4.7	6.3
HADS depression
Median	11.5	10.5	>0.01	11,5	9	>0.01	11	7	>0.01
IQR	6.75	9		8.25	10		6.5	10.5
Mean	11.5	10.5		9	8.4		11	7
± SD	4.2	5.8		4.3	5.9		3.9	5.7

MC medical cannabis, HADS Hospital Anxiety Depression Scale, IQR interquartile range, ± plus/minus, SD standard deviation. Mood disorders were measured with Hospital Anxiety and Depression Scale (HADS) in a cohort of 38 patients with fibromyalgia syndrome treated with medical cannabis at an Italian pain clinic. Wilcoxon signed-rank test was used to evaluate differences between time points

ISSN: 2522-5782